The FDA issued a safety communication that warns about possible Guillain-Barré syndrome (GBS) with respiratory syncytial virus (RSV) vaccines manufactured by Pfizer (Abrysvo) and GSK (Arexvy).

Pfizer’s RSV vaccine also known as Abrysvo is showing the potential to protect adults ages 18 to 59 who are at high risk of getting sick. Pfizer’s RSV vaccine also known as Abrysvo is showing ...

A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival shots from GSK and Moderna, but it may not make much of a difference in the ...